Neuren Pharmaceuticals
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
NNZ-2591 in Prader-Willi syndrome
Investor Information
Welcome
Share Price Information
Shareholder Services
Investor presentations, audio, video
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
ASX Announcements
Annual and Interim Reports
Scientific presentations
Email Alerts
Publications
Home
>
News & Reports
>
ASX Announcements
Font Smaller
Font larger
Print Page
ASX Announcements
29-Apr-2022
Quarterly Activities/Appendix 4C Cash Flow Report
Quarterly Activities/Appendix 4C Cash Flow Report
28-Apr-2022
Virtual AGM online guide
Virtual AGM online guide
28-Apr-2022
Notice of Annual General Meeting/Proxy Form
Notice of Annual General Meeting/Proxy Form
27-Apr-2022
Change in substantial holding
Change in substantial holding
27-Apr-2022
Appendix 4G
Appendix 4G
27-Apr-2022
Annual Report to shareholders
Annual Report to shareholders
25-Mar-2022
FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
23-Mar-2022
FDA approval for Phelan-McDermid IND and Phase 2 trial
FDA approval for Phelan-McDermid IND and Phase 2 trial
11-Mar-2022
Ethics approval for Angelman Phase 2 trial in Australia
Ethics approval for Angelman Phase 2 trial in Australia
4-Mar-2022
S&P DJI Announces March 2022 Quarterly Rebalance
S&P DJI Announces March 2022 Quarterly Rebalance
Pages:
1
2
3
4
5
6
7
8
9
10
...
Next